AlphaMark Advisors LLC Sells 127 Shares of Eli Lilly and Company (NYSE:LLY)

AlphaMark Advisors LLC cut its holdings in Eli Lilly and Company (NYSE:LLY) by 10.4% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,090 shares of the company’s stock after selling 127 shares during the period. AlphaMark Advisors LLC’s holdings in Eli Lilly and Company were worth $848,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Lipe & Dalton bought a new position in Eli Lilly and Company in the 4th quarter worth about $26,000. Tidemark LLC purchased a new position in Eli Lilly and Company during the fourth quarter valued at approximately $29,000. Core Wealth Advisors Inc. increased its holdings in Eli Lilly and Company by 188.2% during the 4th quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock worth $29,000 after acquiring an additional 32 shares during the period. Frank Rimerman Advisors LLC purchased a new stake in Eli Lilly and Company in the 4th quarter worth approximately $37,000. Finally, St. Johns Investment Management Company LLC boosted its holdings in Eli Lilly and Company by 123.3% in the 4th quarter. St. Johns Investment Management Company LLC now owns 67 shares of the company’s stock valued at $39,000 after purchasing an additional 37 shares during the period. Institutional investors own 82.53% of the company’s stock.

Insider Activity

In related news, major shareholder Lilly Endowment Inc sold 1,441 shares of the company’s stock in a transaction on Friday, June 28th. The stock was sold at an average price of $915.02, for a total value of $1,318,543.82. Following the sale, the insider now directly owns 97,367,369 shares of the company’s stock, valued at $89,093,089,982.38. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In related news, major shareholder Lilly Endowment Inc sold 1,441 shares of the business’s stock in a transaction dated Friday, June 28th. The shares were sold at an average price of $915.02, for a total transaction of $1,318,543.82. Following the sale, the insider now owns 97,367,369 shares of the company’s stock, valued at $89,093,089,982.38. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Johna Norton sold 7,056 shares of the firm’s stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $819.38, for a total transaction of $5,781,545.28. Following the transaction, the executive vice president now directly owns 25,428 shares of the company’s stock, valued at approximately $20,835,194.64. The disclosure for this sale can be found here. Insiders sold a total of 791,145 shares of company stock worth $673,704,508 in the last quarter. 0.13% of the stock is owned by company insiders.

Analyst Ratings Changes

LLY has been the topic of a number of recent analyst reports. JPMorgan Chase & Co. increased their price objective on Eli Lilly and Company from $850.00 to $900.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 1st. Truist Financial reissued a “buy” rating and set a $1,000.00 price objective (up previously from $892.00) on shares of Eli Lilly and Company in a report on Tuesday, June 25th. Citigroup upped their price objective on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the stock a “buy” rating in a research report on Tuesday, April 2nd. Argus lifted their target price on shares of Eli Lilly and Company from $770.00 to $840.00 and gave the company a “buy” rating in a research report on Tuesday, May 14th. Finally, Jefferies Financial Group increased their price target on shares of Eli Lilly and Company from $994.00 to $1,015.00 and gave the stock a “buy” rating in a report on Monday, June 24th. Three research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $812.72.

Eli Lilly and Company Trading Up 1.0 %

LLY traded up $8.99 during midday trading on Monday, reaching $914.37. 2,469,029 shares of the company’s stock traded hands, compared to its average volume of 2,933,687. Eli Lilly and Company has a 52 week low of $434.34 and a 52 week high of $916.83. The company has a debt-to-equity ratio of 1.90, a current ratio of 1.35 and a quick ratio of 1.03. The firm has a fifty day moving average of $814.40 and a two-hundred day moving average of $740.86. The stock has a market capitalization of $869.03 billion, a price-to-earnings ratio of 134.66, a P/E/G ratio of 1.97 and a beta of 0.41.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Monday, May 6th. The company reported $2.58 earnings per share for the quarter, beating the consensus estimate of $2.53 by $0.05. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The business had revenue of $8.77 billion for the quarter, compared to analysts’ expectations of $8.94 billion. During the same quarter in the previous year, the business posted $1.62 earnings per share. The firm’s revenue for the quarter was up 26.0% compared to the same quarter last year. On average, equities analysts anticipate that Eli Lilly and Company will post 13.76 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Thursday, August 15th will be given a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 0.57%. The ex-dividend date is Thursday, August 15th. Eli Lilly and Company’s dividend payout ratio is currently 76.58%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.